POT-4 (TFA)

• UNSPSC Description:

  POT-4 TFA (AL-78898A TFA), a Compstatin derivative, is a potent inhibitor of complement factor C3 activation. POT-4 TFA can be used for age-related macular degeneration research[1][2].

• Target Antigen:

  Complement System

• Type:

  Peptides

• Related Pathways:

  Immunology/Inflammation

• Applications:

  Metabolism-protein/nucleotide metabolism

• Field of Research:

  Metabolic Disease

• Assay Protocol:

  https://www.medchemexpress.com/pot-4-tfa.html

• Solubility:

  10 mM in DMSO

• Smiles:

  CN1C2=CC=CC=C2C(C[C@H]3C(N[C@H](C(N[C@H](C(N[C@H](C(NCC(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@H](CSSC[C@@H](C(N[C@H](C(N3)=O)C(C)C)=O)NC([C@@H](NC(C)=O)[C@@H](C)CC)=O)C(N[C@H](C(N)=O)[C@H](O)C)=O)=O)CCCNC(N)=N)=O)CC4=CN=CN4)=O)C)=O)=O)CC5=CNC6=CC=CC=C56)=O)CC(O)=O)=O)CCC(N)=O)=O)=C1.O=C(O)C(F)(F)F

• Molecular Weight:

  1741.87

• References & Citations:

  [1]S. Kaushal, et al. Complement C3 inhibitor POT-4: Clinical Safety of Intravitreal Administration. ARVO Annual Meeting Abstract, 2009 Apr.|[2]Robyn Troutbeck, et al. Therapeutic targeting of the complement system in age-related macular degeneration: a review. Clin Exp Ophthalmol. Jan-Feb 2012;40(1):18-26.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  Phase 2